Tigogenin
Based on 1 Customer Validation
Tigogenin is a steroidal sapogenins. Tigogenin can inhibit adipocytic differentiation and induce osteoblastic differentiation in mouse bone marrow stromal cells. Tigogenin can inhibit cells proliferation and induce apoptosis. Tigogenin can be used for the researches of cancer, inflammation, immunology, metabolic and cardiovascular disease, such as mammary gland carcinoma, rheumatoid arthritis, osteoporosis and atherosclerosis.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度 : 98.0%
- CAS 番号: 77-60-1
- 分子式: C27H44O3
- 分子量:416.64
-
保管条件:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
生物活性
製品説明
体外実験
Tigogenin (10-90 μM, 3 days) promotes bone marrow stromal cells (BMSCs) proliferation in a dose-dependent manner[1].
Tigogenin (10-90 μM, 18 days) decreases lipid accumulation and visfatin secretions in BMSCs[1].
Tigogenin (10-90 μM, 5-18 days) reduces PPAR mRNA and ap2 levels in BMSCs[1].
Tigogenin (10-90 μM, 5 days) increases levels of mRNA for Cbfa1, COL I, OCN and ALP activity in BMSCs[1].
Tigogenin (30 μM, 5-40 mins) activates the phosphorylation of p38 kinase in BMSCs[1].
Tigogenin (40 μM, 24-96 h) inhibits proliferation in rheumatoid arthritis (RA) synoviocytes[2].
Tigogenin (40 μM, 6-24 h) induces apoptosis in RA synoviocytes[2].
Tigogenin (40 μM, 1-24 h) increases P38, COX-2 and PEG2 levels in RA synoviocytes[2].
Tigogenin (20 μM, 24 h) reduces FXR, SHP, and BSEP levels companied with CDCA (HY-76847) in HepG2 cells[3].
Tigogenin (L–serine derivative of Tigogenin) (48 h) inhibits MCF-7 and MDA-MB-231 cells proliferation with IC50 values of 1.5 and 10.5 μM[4].
Tigogenin (L–serine derivative of Tigogenin) (2.8-7 μM, 18 h) induces apoptosis and increases caspase 3/7 activity in MCF-7 cells[4].
Tigogenin (L–serine derivative of Tigogenin) (5 μM, 6 h) reduces TNF-α, IL-1, IL-12, IL-10 and IL-4 levels in THP–1 cells[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:BMSCs
-
Concentration:10, 30 and 90 μM
-
Incubation Time:3 days
-
Result:Promoted proliferation in a dose-dependent manner.
-
Cell Line:BMSCs
-
Concentration:10, 30 and 90 μM
-
Incubation Time:5 or 18 days
-
Result:Reduced PPAR mRNA and ap2 levels.
-
Cell Line:RA synoviocytes
-
Concentration:40 μM
-
Incubation Time:6 and 24 h
-
Result:Induced cell shrinkage, cytoplasm condensation and formation of cytoplasmic filaments.
Increased caspase-3, caspase-8 and caspase-9 activities.
Showed DNA fragmentation.
化学情報
-
CAS 番号 77-60-1
-
性状 Solid
-
分子量 416.64
-
分子式 C27H44O3
-
Color White to off-white
-
SMILES
[H][C@]1(O[C@@]2(OC[C@H](C)CC2)[C@H]3C)C[C@@]4([H])[C@]5([H])CC[C@@]6([H])C[C@@H](O)CC[C@]6(C)[C@@]5([H])CC[C@]4(C)[C@]13[H]
-
別名
チゴゲニン
-
Structure Classification
-
Initial Source
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
溶剤 & 溶解度
体外:
Ethanol : 14.29 mg/mL (34.30 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
純度とドキュメンテーション
-
データシート (277 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
取扱説明書 (2659 KB)
参考文献
[1]. Zhou H, et al. Tigogenin inhibits adipocytic differentiation and induces osteoblastic differentiation in mouse bone marrow stromal cells. Mol Cell Endocrinol. 2007 May 30;270(1-2):17-22. [Content Brief]
[2]. Liagre B, et al. Inhibition of human rheumatoid arthritis synovial cell survival by hecogenin and tigogenin is associated with increased apoptosis, p38 mitogen-activated protein kinase activity and upregulation of cyclooxygenase-2. Int J Mol Med. 2007 Oct;20(4):451-60. [Content Brief]
[3]. Bao R, et al. Dioscin Ameliorates Hyperuricemia-Induced Atherosclerosis by Modulating of Cholesterol Metabolism through FXR-Signaling Pathway. Nutrients. 2022 May 9;14(9):1983. [Content Brief]
[4]. Michalak O, et al. Synthesis and anti-tumour, immunomodulating activity of diosgenin and tigogenin conjugates. J Steroid Biochem Mol Biol. 2020 Apr;198:105573. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| Ethanol | 1 mM | 2.4002 mL | 12.0008 mL | 24.0015 mL | 60.0038 mL |
| 5 mM | 0.4800 mL | 2.4002 mL | 4.8003 mL | 12.0008 mL | |
| 10 mM | 0.2400 mL | 1.2001 mL | 2.4002 mL | 6.0004 mL | |
| 15 mM | 0.1600 mL | 0.8001 mL | 1.6001 mL | 4.0003 mL | |
| 20 mM | 0.1200 mL | 0.6000 mL | 1.2001 mL | 3.0002 mL | |
| 25 mM | 0.0960 mL | 0.4800 mL | 0.9601 mL | 2.4002 mL | |
| 30 mM | 0.0800 mL | 0.4000 mL | 0.8001 mL | 2.0001 mL |